Expert Illustrations & Commentaries Live: The Future of JAK/TYK2 Inhibition in the Treatment of Psoriasis

Released On
February 18, 2022

Expires On
February 18, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Dermatology, Immunology

Topic(s)
Dermatologic Conditions, New Drugs

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by an educational grant from Bristol Myers Squibb

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward the dermatologists, nurse practitioners, and physician assistants who treat patients with dermatologic conditions.

Program Overview

This online, on-demand virtual symposium brings together renowned experts in dermatology to discuss newer treatments for patients with psoriasis. Psoriasis has no clearly defined cause or cure, but it does have a significant impact on quality of life. It is now recognized as a systemic disease associated with psoriatic arthritis and other serious comorbidities. The critical pathogenic pathway in psoriasis is considered to be the interleukin (IL)-23/IL-17 axis. This pathway uses the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway to transduce intracellular signals. Although small molecules that block the JAK/STAT pathway and reduce inflammation have been developed, their relative nonspecific nature and toxicity have hindered their use in patients with psoriasis. Current research is focused on tyrosine kinase 2 (TYK2) inhibitors, which have more favorable efficacy and safety profiles.

In this CME activity, a panel of experts discusses treatment options for patients with psoriasis, focusing on newer TYK2 inhibitors. The program includes a short, animated video that illustrates the mechanism of action of newer therapeutic agents in psoriasis.

This educational activity is an archive of the live virtual symposium, held on January 25, 2022.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the etiology, pathophysiology, and important considerations in the diagnosis of psoriasis.
  • Evaluate the latest data on the efficacy, safety, dosing, and administration of novel TYK2 inhibitors for patients with psoriasis.
  • Integrate targeted TYK2 inhibitors into the treatment of psoriasis.

Faculty

FACULTY_NAME

April W. Armstrong, MD, MPH

Professor of Dermatology
Associate Dean for Clinical Research
Keck School of Medicine at USC
University of Southern California
Los Angeles, CA

FACULTY_NAME

James Q. Del Rosso, DO, FAOCD

Research Director/Principal Investigator
JDR Dermatology Research
Las Vegas, NV
Senior Vice President of Clinical Research and Strategic Development
Advanced Dermatology & Cosmetic Surgery
Maitland, FL

FACULTY_NAME

Linda F. Stein Gold, MD

Director, Dermatology Clinical Research
Head, Division of Dermatology
Henry Ford Health System
Detroit, MI


Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

April W. Armstrong, MD, MPH
  • Grant/Research support: Bristol Myers Squibb, Dermavant Sciences, Dermira, LEO Pharma, Eli Lilly and Company, Pfizer, UCB
  • Consultant: AbbVie, ASLAN Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Dermira, EPI Health, Incyte, Janssen, LEO Pharma, Lilly, MS Pharma, Novartis, Ortho Dermatologics, Parexel, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharmaceutical Industries, UCB
James Q. Del Rosso, DO, FAOCD
  • Grant/Research support: Aclaris Therapeutics, Almirall, Amgen Oncology (Celgene), AnaptysBio, Arcutis Biotherapeutics, Athene, Bausch Health (Ortho Dermatology), Biorasi, Botanix Pharmaceuticals, Brickell Biotech, Cara Therapeutics, Cassiopea SpA, Dermavant Sciences, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO Pharma, Eli Lilly and Company (Dermira), Novan, Pfizer, Ralexar Therapeutics, Regeneron Pharmaceuticals, Sol-Gel Technologies, Sun Pharmaceutical Industries, UCB, VYNE Therapeutics
  • Consultant: AbbVie, Aclaris Therapeutics, Almirall, Amgen Oncology, Arcutis Biotherapeutics, Bausch Health (Ortho Dermatologics), Biofrontera, BioPharmX, Blue Creek Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cassiopea SpA, Dermata Therapeutics, Dermavant Sciences, Encore Pharmaceuticals, EPI Health, Evommune, Ferndale Pharmaceuticals, Galderma, Sanofi Genzyme, Incyte, Jem Health, La Roche-Posay, LEO Pharma, Eli Lilly and Company (Dermira), MC2 Therapeutics, Novan, Pfizer, Regeneron Pharmaceuticals, Sanofi-Sente, Sol-Gel Technologies, Sonoma (IntraDerm), Sun Pharmaceutical Industries, UCB, Verrica Pharmaceuticals, VYNE Therapeutics
  • Speaker’s bureau: Aclaris Therapeutics, Almirall, Amgen Oncology, Bausch Health (Ortho Dermatologics); Biofrontera, BioPharmX, Bristol Myers Squibb, Encore Pharmaceuticals, EPI Health, Ferndale Pharmaceuticals, Galderma, Genentech, Incyte, Jem Health, LEO Pharma, Eli Lilly and Company (Dermira), Pfizer, Regeneron Pharmaceuticals, Sanofi-Genzyme, Sun Pharmaceutical Industries, UCB, Verrica Pharmaceuticals, VYNE Therapeutics
Linda F. Stein Gold, MD
  • Grant/Research support: AbbVie, Amgen Oncology, Arcutis Biotherapeutics, Bristol Myers Squibb, Denova Medical, Novartis, Pfizer, UCB
  • Consultant: AbbVie, Amgen Oncology, Arcutis Biotherapeutics, Bristol Myers Squibb, Denova Medical, Novartis, Pfizer, UCB
  • Speaker’s bureau: Amgen Oncology, Arcutis Biotherapeutics, Bristol Myers Squibb, Pfizer, UCB

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.